IC
ABVX

Ikarian Capital’s Abivax ABVX Stock Holding History

Ikarian Capital’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$43.4M Buy
328,635
+271,000
+470% +$30.7M 4.67% 3
2026
Q1 		$6.23M Sell
57,635
-148,350
-72% -$17.6M 0.51% 51
2025
Q4 		$29.1M Sell
205,985
-190,113
-48% -$20.7M 2.27% 6
2025
Q3 		$33.4M Buy
+396,098
New +$24.3M 3.37% 5

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ikarian Capital's ABVX Position: Q2 2026 in Review

Ikarian Capital increased its Abivax (ABVX) stake by 470% in Q2 2026, buying an estimated $30.7M and bringing the position to 328,635 shares worth $43.4M. The position accounts for 4.67% of the portfolio, ranked #3.

Ikarian Capital first reported a position in ABVX in Q3 2025 and has held it in 4 quarters since. 302 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • Ikarian Capital held 328,635 shares of Abivax worth $43.4M as of Q2 2026.
  • Ikarian Capital bought 271,000 Abivax shares in Q2 2026, an estimated $30.7M.
  • Abivax made up 4.67% of Ikarian Capital's portfolio in Q2 2026, its #3 holding.
  • Ikarian Capital first reported a position in Abivax in Q3 2025 and has held it in 4 quarters since.
  • 302 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.